

## INTERNATIONAL SEARCH REPORT

International Application No  
/GB2004/002351

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C07K16/08 C07K16/12 C07K16/14 C07K16/16 C07K16/18  
 A61P31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MAYER-CN ET AL.: "Antitoxin therapy for botulinum intoxication" REVIEWS IN MEDICAL MICROBIOLOGY, vol. 12, no. 1, January 2001 (2001-01), pages 29-37, XP002299273. the whole document	1-21
A	MULLER B H ET AL: "Phage-displayed and soluble mouse scFv fragments neutralize rabies virus." JOURNAL OF VIROLOGICAL METHODS. SEP 1997, vol. 67, no. 2, September 1997 (1997-09), pages 221-233, XP002299274 ISSN: 0166-0934 abstract	1-21

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 October 2004

21/10/2004

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patenttaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-3040, Tx. 31 661 epo nl  
 Fax: (+31-70) 340-3016

Authorized officer

Lechner, O

## INTERNATIONAL SEARCH REPORT

ttional Application No  
/GB2004/002351

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>STEELE E J ET AL: "Further evidence for cross-linking as a protective factor in experimental cholera: properties of antibody fragments." THE JOURNAL OF INFECTIOUS DISEASES. AUG 1975, vol. 132, no. 2, August 1975 (1975-08), pages 175-180, XP009037451 ISSN: 0022-1899 abstract</p> <p>-----</p> <p>ISMAIL M ET AL: "Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use." TOXICON : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXICOLOGY. NOV 1998, vol. 36, no. 11, November 1998 (1998-11), pages 1523-1528, XP002299275 ISSN: 0041-0101 the whole document</p> <p>-----</p> <p>BEHR T M ET AL: "Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?" CANCER. 15 DEC 1997, vol. 80, no. 12 Suppl., 15 December 1997 (1997-12-15), pages 2436-2457, XP002299276 ISSN: 0008-543X the whole document</p> <p>-----</p>	1-21
P,A	<p>MAYERS CARL N ET AL: "Anti-immunoglobulin responses to IgG, F(ab')2, and Fab botulinum antitoxins in mice." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol. 25, no. 3, August 2003 (2003-08), pages 397-408, XP009037543 ISSN: 0892-3973 the whole document</p> <p>-----</p>	1-21

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/002351

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 22 because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: 22 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

International Application No. PCT/GB2004/002351

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210****Continuation of Box II.1**

Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

**Continuation of Box II.2****Claims Nos.: 22**

The application contains two claims numbered as claim 21. For the sake of clarity second claim 21 is referred to as claim 22.

Claim 22 does not state any (essential) technical feature of an invention, thus, it is considered to lack clarity in the sense of Art. 6, PCT to such an extent, that it was not searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

**BEST AVAILABLE COPY**